Altamira Therapeutics Announces Publication Of Results From Bentrio Trial In Seasonal Allergic Rhinitis In Peer Reviewed Journal

4/24/24 8:48:31 AM ET

$CYTO

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CYTO alert in real time by email

Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published in Allergy journal
Study met primary efficacy endpoint of improvement in nasal symptoms (p = 0.013)
Corroborated by statistically significant improvement in health-related quality of life and reduced need for relief medication
Study outcomes support plans for further international expansion

Get the next $CYTO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CYTO

Date	Price Target	Rating	Analyst

More analyst ratings

$CYTO
Press Releases

Fastest customizable press release news feed in the world

Altamira Therapeutics Provides Update on Nasdaq Listing
Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that it no longer complied with Rule 5550(a)(2) of Nasdaq's Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company's listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. The letter stated that the Company is not eligible for any cure period
10/4/24 4:01:00 PM ET
$CYTO
Biotechnology: Pharmaceutical Preparations
Health Care
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Certification to ISO 13485 extended to also include production process Supports Bentrio growth strategy together with strategic contract manufacturer and expanding network of international distributors Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO) today announced that its associate company Altamira Medica Ltd. obtained extended ISO 13485 certification for its quality management system, including henceforth also production activities. With this extension, the quality management system has been certified for the whole design, development, production and distribution cycle for Altamira Medica's Bentrio® nasal
9/27/24 9:01:00 AM ET
$CYTO
Biotechnology: Pharmaceutical Preparations
Health Care
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ETContinued progress within core activities in RNA delivery, supported by move into new R&D facilities Publications by independent research groups provide fresh evidence of effective mRNA delivery to extrahepatic targets Major territory expansion with two distribution partners for Bentrio® Financial results presented for first time in US dollars rather than Swiss francs Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business
9/24/24 8:01:00 AM ET
$CYTO
Biotechnology: Pharmaceutical Preparations
Health Care

Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
Hamilton, Bermuda, April 10, 2024 (GLOBE NEWSWIRE) -- Management to host conference call today, April 10, at 8.30 a.m. EDTRNA delivery business progressing with new collaborations, potential new applicationsPartnering of legacy assets underway as Company transitions to focused RNA delivery technology providerAchieved 85% reduction in net loss to CHF 3.9 million and eliminated financial debtFinished year with shareholders' equity of CHF 6.5 million, improved by CHF 14.8 million HAMILTON, BERMUDA -- April 10, 2024 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond th
4/10/24 8:00:00 AM ET
$CYTO
Biotechnology: Pharmaceutical Preparations
Health Care
Altamira Therapeutics Provides Business Update, Reports FY 2022 Financial Results
Management will host an investor conference call today, May 16th, at 8 a.m. EasternCompany is advancing OligoPhore™ / SemaPhore™ platform for extrahepatic RNA delivery and efficient endosomal release; expects first research collaborations with biopharmaceutical companies in 2023Filed IND submission with FDA for AM-125 in acute vestibular syndrome‘Showcase' RNA development programs AM-401 and AM-411 progressing in KRAS-driven cancers and rheumatoid arthritis, targeting INDs in 2024Divestiture or partnering of legacy assets remains a key strategic focusTop-line data from full NASAR trial with Bentrio in seasonal allergic rhinitis expected in the second quarterHAMILTON, BERMUDA / ACCESSWIRE / M
5/16/23 7:30:00 AM ET
$CYTO
Biotechnology: Pharmaceutical Preparations
Health Care
Altamira Therapeutics Provides Business Update and Reports Second Half and Full Year 2021 Financial Results
Management will host an investor conference call today, Tuesday, at 8 a.m. Eastern.Company pivots towards RNA therapeutics and its OligoPhore™ / SemaPhore™ platform for extrahepatic RNA deliverEstablished new business unit, OTC Consumer Health, to support global commercialization of Bentrio nasal spray and successfully established distribution partners covering more than 20 countries so far.Reported completion of enrollment into Bentrio™ house dust mite clinical trial with expected top-line results planned for 2Q-22, and initiation of "COVAMID" clinical trial in acute COVID-19.Completed patient enrollment in Part B of Phase 2 ‘TRAVERS' clinical trial evaluating AM-125 in acute vertigo; expec
4/12/22 7:30:00 AM ET
$CYTO
Biotechnology: Pharmaceutical Preparations
Health Care

$CYTO
Leadership Updates

Live Leadership Updates

Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its First Half 2024 Financial Results and Business Update Call on Tuesday, September 24, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts. Webcast Access: Event: Altamira Therapeutics First Half 2024 Financial Results and Business Update CallDate: Tuesday, September 24, 2024Time: 8:30 am ET We
9/20/24 9:01:00 AM ET
$CYTO
Biotechnology: Pharmaceutical Preparations
Health Care
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its Full Year 2023 Financial Results and Business Update Call on Friday, April 10, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts. Webcast Access: Event: Altamira Therapeutics Full Year 2023 Financial Results and Business Update CallDate: Wednesday, April 10, 2024Time: 8:30 am EDTWebcast URL
4/4/24 8:45:00 AM ET
$CYTO
Biotechnology: Pharmaceutical Preparations
Health Care
Altamira Therapeutics to Host Investor & Business Update Call on December 11th
HAMILTON, BERMUDA , Dec. 05, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA--December 5, 2023--Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it will host an Investor and Business Update Call on Monday, December 11, 2023, 8:30 a.m. ET. The presentation will be available via teleconference or webcast with audio and presenter-controlled slides. Webcast Access: Date: Monday, December 11, 2023Time: 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)Webcast URL: https://edge.media-server.com/mmc/p/k7s8zdkg Register for Teleconference:
12/5/23 12:54:05 PM ET
$CYTO
Biotechnology: Pharmaceutical Preparations
Health Care

Altamira Therapeutics Announces Publication Of Results From Bentrio Trial In Seasonal Allergic Rhinitis In Peer Reviewed Journal

Chat with this insight

Recent Analyst Ratings for
$CYTO

$CYTO
Press Releases

Fastest customizable press release news feed in the world

Altamira Therapeutics Provides Update on Nasdaq Listing

Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results

$CYTO
Financials

Live finance-specific insights

Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results

Altamira Therapeutics Provides Business Update, Reports FY 2022 Financial Results

Altamira Therapeutics Provides Business Update and Reports Second Half and Full Year 2021 Financial Results

$CYTO
SEC Filings

SEC Form 6-K filed by Altamira Therapeutics Ltd.

SEC Form 6-K filed by Altamira Therapeutics Ltd.

SEC Form 6-K filed by Altamira Therapeutics Ltd.

$CYTO
Leadership Updates

Live Leadership Updates

Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024

Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024

Altamira Therapeutics to Host Investor & Business Update Call on December 11th

$CYTO
Market Insights

Live Market Insights

Altamira Therapeutics Publishes Preclinical Data For Treatment Of Abdominal Aortic Aneurysm With SOD2 mRNA Delivered By SemaPhore Nanoparticles

Altamira Therapeutics Highlights Review Article Published On Use Of Betahistine In Vertigo Management

Altamira Therapeutics Provides Business Update On RNA Delivery Platform; Announces Improvement In RNA Nanoparticle Stability, Pursues Partnering Opportunities For AM-125 In Vertigo And CNS Indications, And Switches Financial Reporting From Swiss Francs To US Dollars

$CYTO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Altamira Therapeutics Ltd.

SEC Form SC 13D/A filed by Altamira Therapeutics Ltd. (Amendment)

SEC Form SC 13D/A filed by Altamira Therapeutics Ltd. 0.2 (Amendment)

Altamira Therapeutics Announces Publication Of Results From Bentrio Trial In Seasonal Allergic Rhinitis In Peer Reviewed Journal

Chat with this insight

Recent Analyst Ratings for $CYTO

$CYTO Press Releases

Fastest customizable press release news feed in the world

Altamira Therapeutics Provides Update on Nasdaq Listing

Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results

$CYTO Financials

Live finance-specific insights

Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results

Altamira Therapeutics Provides Business Update, Reports FY 2022 Financial Results

Altamira Therapeutics Provides Business Update and Reports Second Half and Full Year 2021 Financial Results

$CYTO SEC Filings

SEC Form 6-K filed by Altamira Therapeutics Ltd.

SEC Form 6-K filed by Altamira Therapeutics Ltd.

SEC Form 6-K filed by Altamira Therapeutics Ltd.

$CYTO Leadership Updates

Live Leadership Updates

Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024

Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024

Altamira Therapeutics to Host Investor & Business Update Call on December 11th

$CYTO Market Insights

Live Market Insights

Altamira Therapeutics Publishes Preclinical Data For Treatment Of Abdominal Aortic Aneurysm With SOD2 mRNA Delivered By SemaPhore Nanoparticles

Altamira Therapeutics Highlights Review Article Published On Use Of Betahistine In Vertigo Management

Altamira Therapeutics Provides Business Update On RNA Delivery Platform; Announces Improvement In RNA Nanoparticle Stability, Pursues Partnering Opportunities For AM-125 In Vertigo And CNS Indications, And Switches Financial Reporting From Swiss Francs To US Dollars

$CYTO Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Altamira Therapeutics Ltd.

SEC Form SC 13D/A filed by Altamira Therapeutics Ltd. (Amendment)

SEC Form SC 13D/A filed by Altamira Therapeutics Ltd. 0.2 (Amendment)

Recent Analyst Ratings for
$CYTO

$CYTO
Press Releases

$CYTO
Financials

$CYTO
SEC Filings

$CYTO
Leadership Updates

$CYTO
Market Insights

$CYTO
Large Ownership Changes